Response of CD44+/CD24-/low breast cancer stem/progenitor cells to tamoxifen‑ and doxorubicin‑induced autophagy

Yenigun,Vildan  Betul; Ozpolat,Bulent; Kose,Gamze  Torun

doi:10.3892/ijmm.2013.1342

Response of CD44+/CD24-/low breast cancer stem/progenitor cells to tamoxifen‑ and doxorubicin‑induced autophagy

Authors:
- Vildan Betul Yenigun
- Bulent Ozpolat
- Gamze Torun Kose
View Affiliations

Affiliations: Department of Genetics and Bioengineering, Yeditepe University, Istanbul 34755, Turkey, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Published online on: April 10, 2013 https://doi.org/10.3892/ijmm.2013.1342
Pages: 1477-1483

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The cancer stem cell hypothesis emphasizes that cancers are driven by cells having stem cell properties, and it is believed that cancer stem cells (CSCs) may be responsible for resistance against therapeutic approaches and for recurrent tumors. Since the biology of the normal breast requires large numbers of stem cells, it has been thought that breast stem cells play an important role in initiating breast cancer. A better characterization of breast CSCs appears to be an essential step to improve the understanding of the biology of breast cancer and its management. The scope of this study was to isolate breast CSCs from a breast cancer cell line (MCF-7) using cell surface markers, and to test whether these cells have any resistance to autophagic cell death mechanisms mediated by commonly used chemotherapies and hormonal therapies such as doxorubicin (adriamycin) and tamoxifen (anti-estrogen), respectively. For this purpose, the CD44+/CD24-/low MCF-7 breast cancer stem/progenitor cell population was isolated and treated with doxorubicin or tamoxifen and evaluated for their response to growth, autophagy and apoptosis. Our findings suggest that CD44+/CD24-/low cells were less sensitive to doxorubicin, but did not demonstrate a significant difference towards tamoxifen in regards to the induction of autophagy.

View Figures

View References

1	Gustafsson JA: Novel aspects of estrogen action. J Soc Gynecol Investig. 7(Suppl 1): S8–S9. 2000. View Article : Google Scholar : PubMed/NCBI
2	Moggs JG and Orphanides G: Estrogen receptors: orchestrators of pleiotropic cellular responses. EMBO Rep. 2:775–781. 2001. View Article : Google Scholar : PubMed/NCBI
3	Cos S, González A, Martínez-Campa C, Mediavilla MD, Alonso-González C and Sánchez-Barceló EJ: Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev. 30:118–128. 2006. View Article : Google Scholar : PubMed/NCBI
4	Fornari FA, Randolph JK, Yalowich JC, Ritke MK and Gewirtz DA: Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol. 45:649–656. 1994.PubMed/NCBI
5	Akar U, Chaves-Reyez A, Barria M, Tari A, Sanguino A, Kondo Y, Kondo S, Arun B, Lopez-Berestein G and Ozpolat B: Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy. 4:669–679. 2008. View Article : Google Scholar : PubMed/NCBI
6	Deroo BJ and Korach KS: Estrogen receptors and human disease. J Clin Invest. 116:561–570. 2006. View Article : Google Scholar : PubMed/NCBI
7	Shang Y, Hu X, DiRenzo J, Lazar MA and Brown M: Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell. 103:843–852. 2000. View Article : Google Scholar : PubMed/NCBI
8	Bursch W, Ellinger A, Kienzl H, Török L, Pandey S, Sikorska M, Walker R and Hermann RS: Active cell death induced by the anti-estrogens tamoxifen and ICI 164 384 in human mammary carcinoma cells (MCF-7) in culture: the role of autophagy. Carcinogenesis. 17:1595–1607. 1996. View Article : Google Scholar : PubMed/NCBI
9	Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, Sphicas E, Domingo D and Yahalom J: A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res. 61:439–444. 2001.PubMed/NCBI
10	Charafe-Jauffret E, Ginestier C and Birnbaum D: Breast cancer stem cells: tools and models to rely on. BMC Cancer. 9:2022009. View Article : Google Scholar : PubMed/NCBI
11	Wang Y, Yang J, Zheng H, Tomasek GJ, Zhang P, McKeever PE, Lee EY and Zhu Y: Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell. 15:514–526. 2009. View Article : Google Scholar
12	Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili MH, Radisky DC, Ferrone S and Knutson KL: Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 69:2887–2895. 2009. View Article : Google Scholar : PubMed/NCBI
13	Charafe-Jauffret E, Monville F, Ginestier C, Dontu G, Birnbaum D and Wicha MS: Cancer stem cells in breast: current opinion and future challenges. Pathobiology. 75:75–84. 2008. View Article : Google Scholar : PubMed/NCBI
14	Dean M, Fojo T and Bates S: Tumour stem cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005. View Article : Google Scholar
15	Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H and Sorrentino BP: The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med. 7:1028–1034. 2001. View Article : Google Scholar : PubMed/NCBI
16	Hait WN and Yang JM: Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it. Semin Oncol. 32(Suppl 7): S16–S21. 2005. View Article : Google Scholar : PubMed/NCBI
17	Wolman SR, Heppner GH and Wolman E: New directions in breast cancer research. FASEB J. 11:535–543. 1997.PubMed/NCBI
18	Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA and Daidone MG: Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 65:5506–5511. 2005. View Article : Google Scholar : PubMed/NCBI
19	Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
20	Yorimitsu T and Klionsky DJ: Autophagy: molecular machinery for self-eating. Cell Death Differ. 12(Supp 2): S1542–S1552. 2005. View Article : Google Scholar : PubMed/NCBI
21	Shintani T and Klionsky DJ: Autophagy in health and disease: a double-edged sword. Science. 306:990–995. 2004. View Article : Google Scholar : PubMed/NCBI
22	Ravikumar B, Moreau K, Jahreiss L, Puri C and Rubinsztein DC: Plasma membrane contributes to the formation of pre-autophagosomal structures. Nat Cell Biol. 12:747–757. 2010. View Article : Google Scholar : PubMed/NCBI
23	Abedin MJ, Wang D, McDonnell MA, Lehmann U and Kelekar A: Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ. 14:500–510. 2007. View Article : Google Scholar : PubMed/NCBI
24	Codogno P and Meijer AJ: Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ. 12:1509–1518. 2005. View Article : Google Scholar : PubMed/NCBI
25	Lum JJ, Bauer DE, Kong M, Harris MH, Li C, Lindsten T and Thompson CB: Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell. 120:237–248. 2005. View Article : Google Scholar : PubMed/NCBI
26	Beau I, Mehrpour M and Codogno P: Autophagosomes and human diseases. Int J Biochem Cell Biol. 43:460–464. 2011. View Article : Google Scholar : PubMed/NCBI
27	Schneider L and Zhang J: Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson’s disease. Mol Neurodegener. Apr 13–2010.(Epub ahead of print). View Article : Google Scholar
28	Weissman IL, Anderson DJ and Gage F: Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. Annu Rev Cell Dev Biol. 17:387–403. 2001. View Article : Google Scholar : PubMed/NCBI
29	Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV and Varticovski L: Brca1 breast tumors contain distinct CD44⁺/CD24⁻ and CD133⁺ cells with cancer stem cell characteristics. Breast Cancer Res. 10:R102008. View Article : Google Scholar : PubMed/NCBI
30	Fillmore CM and Kuperwasser C: Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 10:R252008. View Article : Google Scholar : PubMed/NCBI
31	Kim HJ, Kim JB, Lee KM, Shin I, Han W, Ko E, Bae JY and Noh DY: Isolation of CD24^high and CD24^low/− cells from MCF-7: CD24 expression is positively related with proliferation, adhesion and invasion in MCF-7. Cancer Lett. 258:98–108. 2007.
32	Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J and Chang JC: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 100:672–679. 2008. View Article : Google Scholar : PubMed/NCBI